Biotherapeutics & Monoclonal Antibodies (mAbs)

First-in-Class Drugs & Biosimilars

The Fox® System is a game-changing tool for mAb design, production, and biosimilar development, offering high-resolution, residue-level insights into antigen-antibody interactions in days—outpacing traditional techniques like NMR, X-ray crystallography, and cryo-EM. Unlike lower-resolution screening techniques (e.g., SPR, BLI, ITC), Fox Footprinting delivers actionable data critical for therapeutic refinement, accelerating biotherapeutic and mAb discovery & development.

Fox Systems deliver unparalleled precision in mapping epitope and paratope regions in monoclonal antibodies. By selectively modifying solvent-accessible residues, HRPF provides high resolution insights into protein-protein interactions—ensuring a deeper understanding of molecular recognition—critical for optimizing mAb therapeutics.

Aggregation compromises mAb stability, efficacy, and immunogenicity. Fox Footprinting enables high resolution assessment of aggregation-prone regions by tracking changes in solvent accessibility, offering actionable insights into formulation optimization to mitigate aggregation risks.

Regulatory agencies demand rigorous protein HOS characterization for biosimilars. Fox Footprinting provides a relative comparison of reference biologics and biosimilar candidates, detecting structural differences due to manufacturing or formulation variances to ensure comparability and regulatory compliance.

Fox Footprinting assesses how formulation conditions, temperature, and storage impact mAb structural integrity over time. By monitoring solvent-accessible regions, researchers can predict degradation pathways, optimize storage conditions, and enhance shelf-life stability.

Manufacturing processes introduce conformational variations in mAbs. Fox Footprinting enables a direct comparison of structural changes due to pH shifts, excipients, stabilizers, or process modifications, ensuring batch-to-batch consistency and product quality.

Optimizing delivery formulations requires precise protein structure insights. Fox Systems evaluate mAb stability under different delivery conditions, supporting the development of effective IV, subcutaneous, and novel administration strategies without compromising therapeutic integrity.

Request a custom webinar for your lab.